The subject of the tender is the conclusion of active ingredient-related discount agreements in accordance with § 130a para. 8 SGB V for medicinal products for 24 months from 01.07.2024 - 30.06.2026. The contracts relate to all contractual medicines that are dispensed at the expense of the health insurance companies during the term of the contract. As a matter of principle, only prescription medicines are in demand per lot. The invitation to tender is generally based on active ingredients within the meaning of Section 24b (2) AMG, not within the meaning of Section 4 (19) AMG. 141 lots were formed. These are each divided into so-called exchange groups. The DAK-G is authorized by the other substitute funds to carry out the tender in the name of and with effect for them. Further details can be found in the tender documents.

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the above lot, the intention is to establish discount contracts with up to 2 pharmaceutical entrepreneurs (as

individual bidders or as bidder association (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).